Table 1.
Characteristics of included studies
| Author/ year | Country | Sample size cases/controls | Samples | Type of cancer | Detection Method | Microbiome | Outcome | Multivariate analyses | Study design | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Mima/2016 [8] | USA | 1069 | tissue | CRC | PCR | F. nucleatum | OS, DSS | The amount of Fusobacterium nucleatum DNA | P | 7 |
| Neuzillet/2021 [9] | France | 151 | tissue | OSCC | 16S rRNA sequencing | F. nucleatum | PFS, OS | F. nucleatum status, UICC stage, TP53 mutational status | R | 6 |
| Mitsuhashi/2015 [10] | Japan | 283 | tissue | PC | TaqMan gene expression assay | F. nucleatum | DSS | Fusobacterium species, CIMP status, and expression level of microRNA-31 | P | 6 |
| Mohamed/2021 [11] | Norway | 72 (59/13) | saliva | OSCC | NGS | genus Malassezia | OS | salivary carriage of both Candida and Malassezia, age | P | 7 |
| Du/2022 [12] | Sweden | 482 | saliva | NPC | 16S rRNA sequencing | microbial diversity | OS, DSS | Faith’s PD diversity, Observed ASVs diversity, Shannon diversity | P | 7 |
| Wei/2016 [13] | China | 180 | tissue | CRC | RNAsequencing and PCR | F. nucleatum | DFS, OS | CEA, TNM stage, B. fragilis, F. nucleatum | P | 7 |
| Lee/2018 [20] | Korea | 246 | tissues | CRC | PCR | F. nucleatum | DFS, OS | Differentiation, CIMP, Metastatic site, F. nucleatum amount | P | 6 |
| Jeong Oh/2018 [17] | Korea | 593 | tissues | CRC | PCR | F. nucleatum | DFS | No | R | 7 |
| Chen/2020 [18] | Taiwan | 156 | oralbiofilms | ESCC | PCR | P. gingivalis | OS | Clinical stage, P. gingivalis staining, Response to Neoadjuvant, Treatment | P | 8 |
| Yu/2018 [25] | China | 196 | tissue | CRC | RNA-sequencing and PCR | F. nucleatum | RFS | F. nucleatum abundance, AJCC stage | R | 6 |
| Qiao/2022 [24] | China | 802 | tissue | NPC | 16S rRNA sequencing and PCR | bacterial load | DFS, OS | sex, age, stage, pathological type, intratumoral bacterial load, and chemotherapy | R | 7 |
| Gao/2016 [16] | China | 130 (100/30) | tissue | ESCC | PCR | P. gingivalis | OS | No | P | 7 |
| Yamamura/2016 [17] | Japan | 325 | tissues | ESCC | PCR | F. nucleatum | DSS | Performance status, Tumor stage, Fusobacterium | R | 5 |
| Yan/2017 [18] | China | 280 | tissues | CRC | PCR | F. nucleatum | DFS, DSS | Tumor invasion, Lymph node metastasis, Distant metastasis, Serum CEA level, Fusobacterium level | R | 6 |
| Gao/2018 [19] | China | 226 (146/80) | serum | ESCC | ELISA | P. gingivalis | OS | N-stage, IgG (EU), IgA (EU) | P | 7 |
CRC colorectal cancer, DFS disease free survival, DSS Disease Free Survival, ELISA enzyme-linked immunosorbent assay, ESCC esophageal cancer, F. nucleatum Fusobacterium nucleatum, NGS next generation sequencing, NPC nasopharyngeal carcinoma, OS overall survival, OSCC oral squamous cell carcinoma, P Prospective Cohort, PC pancreatic cancer, PCR polymerase chain reaction, PFS progression free survival, P. gingivalis Porphyromonas gingivalis, R Retrospective Cohort, RFS Recurrence free survival. CIMP CpG island methylator phenotype